pimecrolimus topical / Generic mfg. - LARVOL DELTA

Not So Slick: When Neem Oil Ingestion Acute Liver Injury from Neem Oil Ingestion (ACG 2026) - "For his eczema, patient is on pimecrolimus and reported both ingestion and topical application of Neem powder for four weeks prior to admission...Given concern for drug-induced liver injury, the patient was started on intravenous N-acetylcysteine until LFTs have improved by 50%...Given its lipophilic nature, it has a higher absorption and tissue penetration when ingested causing damage to both hepatocytes and biliary canaliculi damage showing an early rise in AST/ALT followed by rise in ALP and bilirubin and bile excretion becomes impaired. When in combination with a secondary assault such as alcohol which increases CYP-mediated toxic metabolite formation and impairs mitochondrial recovery."

Addiction (Opioid and Alcohol) • Atopic Dermatitis • Cardiovascular • Hepatology • Immunology • Liver Failure • Metabolic Disorders

Recent recommendations for the treatment of lupus erythematosus (EADV 2026) - "For limited disease, topical corticosteroids and topical calcineurin inhibitors (tacrolimus, pimecrolimus) are standard; however, recent guidance increasingly favors calcineurin inhibitors or emerging topical Janus kinase (JAK) inhibitors for long-term maintenance to avoid corticosteroid-induced skin atrophy. For widespread, severe, or topically refractory CLE, systemic antimalarials—specifically hydroxychloroquine—remain the undisputed gold-standard first-line systemic intervention...When antimalarials fail, current algorithms prioritize the prompt introduction of second-line conventional immunosuppressants (methotrexate, mycophenolate mofetil, dapsone, or oral retinoids) to accelerate systemic glucocorticoid tapering. A key mandate in modern guidelines is the rapid reduction of prednisone to 5 mg/day or less within six months of initiation...The B-cell inhibitor belimumab and the type I interferon receptor antagonist anifrolumab are advised for patients with severe..."

Cutaneous Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Ophthalmology • Tobacco Cessation • IFNAR2 • TYK2

Blaschko-Linear Lupus Erythematosus in a Pediatric Patient. (PubMed, HCA Healthc J Med) - "The patient was treated with intralesional triamcinolone, topical pimecrolimus, and systemic hydroxychloroquine with an emphasis on strict photo-protection. Despite these therapies the patient's disease persisted."

Journal • Cutaneous Lupus Erythematosus • Dermatology • Immunology • Inflammatory Arthritis • Lupus • Pediatrics

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients (clinicaltrials.gov) - P1 | N=81 | Completed | Sponsor: HK inno.N Corporation | Not yet recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Formulation and Box-Behnken optimization of roflumilast loaded ultradeformable nanotransethosomal gel: physicochemical characterization, stability, dermal permeation, and antipsoriatic efficacy in an imiquimod-induced psoriasis model. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In vivo studies revealed significant PASI score reduction (3.50 ± 0.52 on day 7), enhanced inflammatory biomarker suppression, and improved epidermal repair versus pimecrolimus cream (4.50 ± 0.66, p < 0.01). The optimised roflumilast-loaded ultradeformable transethosomal gel demonstrated improved skin penetration, sustained drug release, and superior preclinical antipsoriatic activity. Further clinical studies are warranted to establish long-term safety and therapeutic efficacy."

Journal • Dermatology • Immunology • Psoriasis

AQUA: A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (clinicaltrials.gov) - P3 | N=464 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

(Pr)ELIDEL (pimecrolimus) cream Now Reimbursed Under Alberta's Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis (Yahoo Finance)

Reimbursement • Atopic Dermatitis

Decoding Sensitive Skin Syndrome: International Expert Advisory Insights on Management From India and the United States of America. (PubMed, J Drugs Dermatol) - "SSS is a clinically relevant condition requiring structured diagnostics, recognition of comorbidities, and integrated treatment. Greater awareness and education are essential to improve care. &nbsp."

Journal • Dermatology

Misinformation, Fear, and Knowledge Gaps: Patient Perspectives on Topical Corticosteroids and Steroid Withdrawal (BAD 2026) - "Although 64.8% (n = 79) of the 122 patients reported understanding TC potency, only 51% of these (40 of 79) correctly identified hydrocortisone as mildly potent, with 35.2% overall (43 of 122) harbouring fears about TC use...Some switched to tacrolimus or pimecrolimus (28%, 9 of 32)...This survey revealed significant patient anxiety fuelled by misinformation, inadequate understanding of steroid potency, and clinician–patient communication gaps. Enhanced patient education, particularly accessible written resources, is urgently needed to counter misconceptions and improve treatment engagement."

Clinical • Atopic Dermatitis • Immunology • Mood Disorders • Psoriasis

Misinformation, Fear, and Knowledge Gaps: Patient Perspectives on Topical Corticosteroids and Steroid Withdrawal (BAD 2026) - "Although 64.8% (n = 79) of the 122 patients reported understanding TC potency, only 51% of these (40 of 79) correctly identified hydrocortisone as mildly potent, with 35.2% overall (43 of 122) harbouring fears about TC use...Some switched to tacrolimus or pimecrolimus (28%, 9 of 32)...This survey revealed significant patient anxiety fuelled by misinformation, inadequate understanding of steroid potency, and clinician–patient communication gaps. Enhanced patient education, particularly accessible written resources, is urgently needed to counter misconceptions and improve treatment engagement."

Clinical • Atopic Dermatitis • Immunology • Mood Disorders • Psoriasis

Benzyl Alcohol as a Clinically Relevant Excipient Allergen: A Case Series from a Tertiary Cutaneous Allergy Centre (BAD 2026) - "The first case involved a 13-year-old girl with atopic dermatitis and a 7-year history of persistent facial dermatitis, partially responsive to pimecrolimus...The fourth case is of a 65-year-old woman with recurrent eyelid dermatitis, in whom patch testing demonstrated positivity to benzyl alcohol, which was an excipient in her topical tacrolimus ointment, and to balsam of Peru. Benzyl alcohol is an uncommon but recognized excipient sensitizer present in a wide range of topical medicaments. This case series highlights the importance of patch testing with patients’ own products, and aims to raises prescriber awareness of excipient allergens as a possible cause of treatment resistance or failure."

Clinical • Allergy • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Immunology

Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics. (PubMed, Med Sci (Basel)) - "Topical calcineurin inhibitors (CNIs), such as tacrolimus and pimecrolimus, are available as a safe, steroid-sparing alternative that directly inhibit calcineurin-mediated activation of T cells and have been shown to be efficacious according to varying clinical study designs including randomized controlled trials, registry studies and meta-analyses...Hence, the role of CNIs in the current AD treatment paradigm is crucial and lies at the interface between topical corticosteroids and systemic immunomodulatory agents. The narrative review discusses recent advances in formulation strategies, combination approaches, and targeted delivery systems, underscoring how CNIs continue to bridge established practice and emerging therapeutic innovation in AD."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics

Elidel-SEA: Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis. (clinicaltrials.gov) - P=N/A | N=130 | Active, not recruiting | Sponsor: BGP Products Operations GmbH, a Viatris company | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Feb 2025 ➔ Mar 2027 | Trial primary completion date: Aug 2024 ➔ Oct 2026

Enrollment closed • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Lichen Sclerosus: A Common but Often Overlooked Condition in Pediatric Patients. (PubMed, Clin Pediatr (Phila)) - "Among 60 patients followed (mean duration = 16.8 months), topical pimecrolimus resolved symptoms in 88.3% and improved skin lesions in 66.6%. Lichen sclerosus should be included in the differential diagnosis for children with urinary symptoms. Clinical awareness and early diagnosis can lead to avoiding unnecessary investigations."

Journal • Dermatology • Infectious Disease • Nephrology • Pediatrics

Demographics, Etiologic Associations, and Treatment Outcomes in Perioral Dermatitis: A Systematic Review (CDA 2026) - "In a single randomized trial, topical praziquantel ointment achieved complete clearance in 45.4% of patients and complete or near-complete clearance in 81.8%. Corticosteroid misuse was the most frequently reported aggravating factor in POD. Oral antibiotics showed the highest and most consistent clearance, particularly in moderate-severe adult disease, while topical antibiotics were most effective in pediatric and milder cases. Pimecrolimus cream improved outcomes versus vehicle but had lower clearance and was evaluated in smaller trials."

Clinical • Review • Dermatitis • Dermatology • Immunology

Synergistic hepatotoxicity of azithromycin and acetaminophen involves liver X receptor α-mediated metabolic dysregulation and endoplasmic reticulum stress. (PubMed, Drug Metab Dispos) - "Pharmacological activation of LXR (using GW3965, LXR agonist) or inhibition of pregnane X receptor (using pimecrolimus) conferred significant protection against liver injury. This suppression disrupts metabolic balance via the LXRα-cytochrome P450/UDP-glucuronosyltransferase axis and exacerbates endoplasmic reticulum stress via the LXRα-lysophosphatidylcholine acyltransferase 3 pathway. Based on the finding of a critical drug-drug interaction, the study cautions against coadministration of azithromycin and acetaminophen and proposes LXRα as a promising target for preventing hepatotoxicity."

Journal • Hepatology • Liver Failure • Metabolic Disorders • CYP2E1

Mupirocin 2% ointment should be included in the treatment armamentarium for balanitis circumscripta plasmacellularis. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Dermatology

Stump pemphigoid - a case report (ISPRM 2026) - "This case highlights the importance of recognizing stump pemphigoid as a potential cause of recurrent bullae in amputees. Early diagnosis and multidisciplinary management are essential to optimize functional recovery and prosthetic use."

Case report • Clinical • CNS Disorders • Immunology • Mood Disorders

Topical nonsteroidal immunomodulators: A post-marketing analysis of the FDA adverse event reporting system (SID 2026) - "Agents analyzed included tacrolimus, pimecrolimus, crisaborole, ruxolitinib, roflumilast, and tapinarof...Newer generation NTIs, such as roflumilast, ruxolitinib, and tapinarof, had fewer application site-related AEs. Integrating safety data into clinical management enables balance between efficacy and patient comfort, while standardized AE reporting in future research is needed for strengthening real-world data."

Adverse events • Immunomodulating • P4 data • Acne Vulgaris • Inflammation

Rare case of a Netherton syndrome in a Bulgarian patient: case presentation and focus on new therapeutic horizons (EADV-Sp 2026) - "After the reevaluation of the diagnosis a systemic therapy with acitretin 10 mg daily, local pimecrolimus 1%, emollients, and bilastine 20 mg once daily was initiated. New hopes are placed on targeted or anti- cytokine therapy, based on inhibiting the inflammatory component of the disease. Innovative therapeutic options, including modern medications such as dupilumab, infliximab, secukinumab, anakinra, omalizumab, and others are the new hope for succesful management of the disease."

Clinical • Atopic Dermatitis • Dermatitis • Food Hypersensitivity • Immunology • Mood Disorders • Psoriasis • Vitiligo

Comparative efficacy of pediatric atopic dermatitis treatments: a network meta-analysis highlighting dupilumab and pimecrolimus for SCORAD and EASI improvement. (PubMed, Front Immunol) - "Cumulative probability rankings indicated Dupilumab (96.0%), Tralokinumab (86.8%), and PEC (69.2%) as the top treatments. For EASI, Pimecrolimus, Dupilumab, and Nemolizumab were superior to Probiotics, with Pimecrolimus showing the highest efficacy (99.9%)...These treatments show potential as favorable options for managing pediatric atopic dermatitis. https://www.crd.york.ac.uk/PROSPERO/view/CRD420250650919, identifier CRD420250650919."

Clinical • Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Topical calcineurin inhibitors and the epidermal barrier in atopic dermatitis. (PubMed, Dermatology) - "TCIs exert their beneficial effects on skin inflammation through selective T-cell modulation without disrupting keratinocyte differentiation or dermal matrix components. For this reason, the general indirect positive effects on skin barrier associated with reduction of skin inflammation is not counterbalanced by intrinsic barrier damaging mechanisms as observed with topical steroids. Further studies are needed to evaluate long-term effects on skin structure, microbiome stability, and their integration into biologic treatment algorithms."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • FLG • LORICRIN

Topical Pimecrolimus for Treatment-Refractory Tazarotene-Induced Photosensitive Facial Erosions. (PubMed, Cureus) - "Subsequent treatment with pimecrolimus 1% cream resulted in progressive clinical improvement, with complete healing of erosions within three months. This case highlights topical calcineurin inhibition as an effective steroid-sparing strategy for persistent retinoid-associated inflammatory dermatoses and underscores the role of cumulative ultraviolet exposure as a potentiating factor."

Journal • Acne Vulgaris • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • CRP

Eosinophilic facial granuloma presenting with an apple-jelly-like appearance on diascopy: a rare clinical finding (EADV-Sp 2026) - "Previous topical treatment administered over several months with pimecrolimus and medium-to high-potency topical corticosteroids had been ineffective...Skin biopsy and subsequent histopathological analysis were essential to establish the correct diagnosis and to guide appropriate therapeutic menagment. In present case, diascopy could have been misleading."

Clinical • Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Sarcoidosis • CD31 • PECAM1

Erythrodermic sarcoidosis with systemic involvement during vaccination for COVID-19: possible links to molecular mimicry (EADV-Sp 2026) - "Results Histology revealed cutaneous sarcoidosis (Fig.2a-d).Systemic immunosuppressive therapy with Methylprednisolone was introduced according to a scheme (in a reduction mode with an initial dose of 40 mg/day intravenously) in combination with topical Pimecrolimus 1% cream twice a day...Fig.3a-d: Patient’s outcome after successful treatment for sarcoidosis. No signs of suberythrodermia"

Cardiovascular • Hepatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Sarcoidosis • Uveitis • Ventricular Tachycardia